Human Anti-Alpha-Synuclein Antibodies for Parkinson's Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and characterizing autoantibodies against α-synuclein are limited by the risk of cross-reactivity, lack of specificity, and the human anti-mouse antibody response, making them unsuitable for therapeutic and diagnostic applications in treating neurodegenerative diseases like Parkinson's disease.
Innovation Solution
Development of human α-synuclein-specific monoclonal antibodies isolated from aged healthy control subjects, which are specific for native, misfolded, or aggregated forms of α-synuclein, minimizing cross-reactivity and avoiding the human anti-mouse antibody response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If murine based antibodies are used to treat Parkinson's disease, then the ability to neutralize neurotoxic aggregates is improved, but the human anti-mouse antibody response causes harmful side effects
Solution Approach 1:
The patent changes the species origin parameter of the antibodies from murine to human. Human monoclonal antibodies are produced by transfecting human B-cell hybridomas with human immunoglobulin gene sequences into mammalian cells, ensuring the antibodies are of human origin and thus avoid triggering the human anti-mouse antibody response while maintaining therapeutic efficacy against α-synuclein aggregates
2Ease of manufacture
If phage displayed antibody library is used to isolate single chain antibody fragments, then the isolation process is simplified, but cross-reactivity against self-antigens and lack of specificity increases
Solution Approach 1:
The patent uses human B-cell hybridomas as an intermediary system that naturally produces high-affinity, specific human antibodies. Instead of using phage display libraries that may produce cross-reactive fragments, the hybridoma cells serve as a biological factory that generates monoclonal antibodies with proven specificity through natural immune selection, eliminating cross-reactivity issues while maintaining ease of production
3Ease of manufacture
If polyclonal antibodies are used for diagnosis and therapy, then the isolation process is simplified, but heterogeneity and contamination with other molecules increase
Solution Approach 1:
The patent extracts a single specific antibody clone from the complex polyclonal antibody mixture by isolating individual B-cells that produce anti-α-synuclein antibodies. Through cloning and hybridoma technology, a single monoclonal antibody population is obtained, ensuring homogeneity and eliminating contamination with other antibody types while maintaining the simplified isolation approach through automated screening methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The human antibodies demonstrate high specificity and efficacy in recognizing α-synuclein, improving motor performance and diagnostic accuracy in transgenic mouse models of Parkinson's disease, with potential therapeutic benefits for synucleinopathic diseases.
Implementation Method 1
human antibodies as well as fragments, derivatives and variants thereof that recognize α-synuclein and aggregated forms of α-synuclein
Data Source
AI summary
Provided are novel human α-synuclein-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.